ArticleBMC veterinary research2025
Oxytocin in horse saliva: validation of a highly sensitive assay and a pilot report about changes in equine gastric ulcer syndrome.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEquine gastric ulcer syndrome (EGUS) is a frequent disease in horses that comprises two different entities: equine squamous gastric disease (ESGD) and equine glandular gastric disease (EGGD). This disease considerably reduces the quality of life of affected horses and can negatively affect performance. Saliva contains biomarkers, such as oxytocin, that have been used as a welfare indicator and can develop a function as a protective factor against stress-induced changes in gastric function due to its gastric antisecretory and antiulcer effects. The objective of this work was to evaluate changes in salivary oxytocin concentrations in healthy and EGUS horses. For this purpose, an immunoassay based on AlphaLISA technology was validated for the quantification of salivary oxytocin and applied in a total of 102 horses divided into 5 groups: 25 with both EGUS, 23 with only EGGD, 21 with only ESGD, 19 horses with other diseases, and 14 healthy horses.
resultsThe analytical validation of the method showed good precision and linearity under dilution. Salivary oxytocin concentrations in healthy horses were higher compared to horses with both ESGD and EGGD and only EGGD. Salivary oxytocin concentrations in horses with only ESGD were higher compared to horses with both ESGD and EGGD and horses with only EGGD. In addition, salivary oxytocin concentrations in horses with other diseases different from ESGD were significantly increased compared to horses with both ESGD and EGGD and horses with only EGGD.
conclusionsThis report validates a new assay that can measure oxytocin in saliva in horses in a precise and accurate way. The lower oxytocin values in horses with EGGD and both EGGD and ESGD than in horses with ESGD, horses with other diseases, and healthy horses could indicate a possible relation of oxytocin with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.